A Study of Zipalertinib in Patients with Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation (REZILIENT2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.